PortfoliosLab logoPortfoliosLab logo
PFE vs. NVAX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PFE vs. NVAX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pfizer Inc. (PFE) and Novavax, Inc. (NVAX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PFE achieves a 8.62% return, which is significantly lower than NVAX's 34.37% return. Over the past 10 years, PFE has outperformed NVAX with an annualized return of 2.17%, while NVAX has yielded a comparatively lower -23.23% annualized return.


PFE

1D
2.23%
1M
1.16%
YTD
8.62%
6M
4.84%
1Y
14.37%
3Y*
-7.54%
5Y*
-3.38%
10Y*
2.17%

NVAX

1D
5.49%
1M
-6.13%
YTD
34.37%
6M
34.98%
1Y
27.36%
3Y*
5.09%
5Y*
-46.69%
10Y*
-23.23%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PFE vs. NVAX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PFE
Pfizer Inc.
8.62%0.65%-2.22%-41.26%-10.41%66.70%3.07%-6.91%24.82%15.90%
NVAX
Novavax, Inc.
34.37%-16.42%67.50%-53.31%-92.81%28.30%2,701.76%-89.18%48.39%-1.59%

Correlation

The correlation between PFE and NVAX is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.28

Correlation (3Y)
Calculated over the trailing 3-year period

0.27

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Dec 13, 1995

0.17

The correlation between PFE and NVAX shifts across timeframes, from 0.17 (all time) to 0.28 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

PFE:

$149.98B

NVAX:

$1.47B

EPS

PFE:

$1.31

NVAX:

-$0.52

PS Ratio

PFE:

2.36

NVAX:

2.56

Total Revenue (TTM)

PFE:

$63.32B

NVAX:

$596.34M

Gross Profit (TTM)

PFE:

$43.91B

NVAX:

$504.72M

EBITDA (TTM)

PFE:

$16.94B

NVAX:

-$57.01M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PFE vs. NVAX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PFE
PFE Risk / Return Rank: 6363
Overall Rank
PFE Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
PFE Sortino Ratio Rank: 5959
Sortino Ratio Rank
PFE Omega Ratio Rank: 5757
Omega Ratio Rank
PFE Calmar Ratio Rank: 6969
Calmar Ratio Rank
PFE Martin Ratio Rank: 6666
Martin Ratio Rank

NVAX
NVAX Risk / Return Rank: 5959
Overall Rank
NVAX Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
NVAX Sortino Ratio Rank: 6161
Sortino Ratio Rank
NVAX Omega Ratio Rank: 5757
Omega Ratio Rank
NVAX Calmar Ratio Rank: 6161
Calmar Ratio Rank
NVAX Martin Ratio Rank: 5959
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PFE vs. NVAX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and Novavax, Inc. (NVAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PFENVAXDifference
Sharpe ratioReturn per unit of total volatility

+0.21

Sortino ratioReturn per unit of downside risk

-0.08

Omega ratioGain probability vs. loss probability

1.13

1.13

0.00

Calmar ratioReturn relative to maximum drawdown

1.26

0.76

+0.49

Martin ratioReturn relative to average drawdown

2.54

1.49

+1.05

PFE vs. NVAX - Sharpe Ratio Comparison

The current PFE Sharpe Ratio is 0.61, which is higher than the NVAX Sharpe Ratio of 0.40. The chart below compares the historical Sharpe Ratios of PFE and NVAX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PFE vs. NVAX - Drawdown Comparison

The maximum PFE drawdown since its inception was -69.24%, smaller than the maximum NVAX drawdown of -98.82%. Use the drawdown chart below to compare losses from any high point for PFE and NVAX.


Loading charts...

Drawdown Indicators


PFENVAXDifference

Max Drawdown

Largest peak-to-trough decline

-69.24%

-98.82%

+29.58%

Max Drawdown (1Y)

Largest decline over 1 year

-11.47%

-35.94%

+24.47%

Max Drawdown (3Y)

Largest decline over 3 years

-40.75%

-74.11%

+33.36%

Max Drawdown (5Y)

Largest decline over 5 years

-58.96%

-98.61%

+39.65%

Max Drawdown (10Y)

Largest decline over 10 years

-58.96%

-98.82%

+39.86%

Current Drawdown

Current decline from peak

-45.76%

-97.18%

+51.42%

Average Drawdown

Average peak-to-trough decline

-22.90%

-70.76%

+47.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.68%

18.46%

-12.78%

Volatility

PFE vs. NVAX - Volatility Comparison

The current volatility for Pfizer Inc. (PFE) is 5.08%, while Novavax, Inc. (NVAX) has a volatility of 23.98%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than NVAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PFENVAXDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.08%

23.98%

-18.90%

Volatility (6M)

Calculated over the trailing 6-month period

14.72%

52.24%

-37.52%

Volatility (1Y)

Calculated over the trailing 1-year period

23.85%

68.90%

-45.05%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

25.49%

106.10%

-80.61%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.89%

115.50%

-91.61%

Dividends

PFE vs. NVAX - Dividend Comparison

PFE's dividend yield for the trailing twelve months is around 6.57%, while NVAX has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
NVAX
Novavax, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PFE
Pfizer Inc.
6.57%6.91%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.53%3.69%3.47%

Financials

PFE vs. NVAX - Financials Comparison

This section allows you to compare key financial metrics between Pfizer Inc. and Novavax, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B25.00B20222023202420252026
14.45B
139.51M
(PFE) Total Revenue
(NVAX) Total Revenue
Values in USD except per share items

PFE vs. NVAX - Profitability Comparison

The chart below illustrates the profitability comparison between Pfizer Inc. and Novavax, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-50.0%0.0%50.0%100.0%20222023202420252026
67.3%
78.0%
Portfolio components
PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.

NVAX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novavax, Inc. reported a gross profit of 108.82M and revenue of 139.51M. Therefore, the gross margin over that period was 78.0%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.

NVAX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novavax, Inc. reported an operating income of -15.43M and revenue of 139.51M, resulting in an operating margin of -11.1%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.

NVAX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novavax, Inc. reported a net income of -9.49M and revenue of 139.51M, resulting in a net margin of -6.8%.


Frequently Asked Questions


PFE and NVAX have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NVAX has higher volatility (23.98%) compared to PFE (5.08%). In terms of maximum drawdown, PFE dropped -69.24% vs NVAX's -98.82%.

PFE currently has the higher Sharpe Ratio (0.61 vs 0.40), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PFE and NVAX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer